Thierry Andre et al., 2009-07-01: Final MOSAIC analysis at six years: overall survival 78.5% with FOLFOX4 versus 76.0% with LV5FU2 (2.5 points, borderline), 72.9% versus 68.7% in stage III, and no overall-survival difference in stage II. Five-year disease-free survival 73.3% versus 67.4%.
Six-year OS rates were 78.5% and 76.0% in the FOLFOX4 and LV5FU2 groups, respectively (HR = 0.84; 95% CI, 0.71 to 1.00; P = .046) … No difference in OS was seen in the stage II population.
Results (journal p. 3109)
Thierry Andre et al., 2009-07-01: Final MOSAIC analysis at six years: overall survival 78.5% with FOLFOX4 versus 76.0% with LV5FU2 (2.5 points, borderline), 72.9% versus 68.7% in stage III, and no overall-survival difference in stage II. Five-year disease-free survival 73.3% versus 67.4%. Funding: Sanofi-Aventis (successor to Sanofi-Synthelabo) per the 2004 report and trial sponsorship; individual disclosures for this paper not captured. Comparator: LV5FU2 alone (standard treatment). The stage II null result is the part that bears on C7's implicit claim about stage II benefit; the authors' conclusion still recommends oxaliplatin 'for patients with stage III disease'. Study type: randomized trial.
